Allogeneic bone marrow transplantation in the developing world: experience from a center in India

被引:44
作者
Chandy, M [1 ]
Srivastava, A [1 ]
Dennison, D [1 ]
Mathews, V [1 ]
George, B [1 ]
机构
[1] Christian Med Coll Hosp, Dept Hematol, Vellore 632004, Tamil Nadu, India
关键词
bone marrow transplantation; developing countries;
D O I
10.1038/sj.bmt.1702869
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
We describe our experience of setting up an allogeneic BMT program at the Christian Medical College Hospital, Vellore over a period of 13 years, from October 1986 to December 1999. Two hundred and twenty-one transplants were performed during this period in 214 patients, with seven patients undergoing second transplants. Indication for BMT were thalassemia major - 106 (48%), CML - 30, AML - 35, ALL - 10, SAA - 22, MDS - six and six for other miscellaneous disorders. The mean age of this patient cohort was 15.6 years (range 2-52). Graft-versus-host disease of grades III and IV was seen in 36 patients (17%) and this was the primary cause of death in 20 patients (9.2%). All patients and donors were CMV IgG positive. Sepsis was the primary cause of death in 16 patients (7.4%), 10 bacterial, four fungal and two viral, One hundred and ten of this series of patients are alive and disease free (50%) with a median follow-up of 24 months (range 2-116). These results are comparable to those achieved for patients with similar disease status in transplant units in the Western world and cost a mean of US$15 000.
引用
收藏
页码:785 / 790
页数:6
相关论文
共 22 条
[1]   THE INCIDENCE OF ANTIBIOTIC-RESISTANCE IN AEROBIC FECAL FLORA IN SOUTH-INDIA [J].
AMYES, SGB ;
TAIT, S ;
THOMSON, CJ ;
PAYNE, DJ ;
NANDIVADA, LS ;
JESUDASON, MV ;
MUKUNDAN, UD ;
YOUNG, HK .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1992, 29 (04) :415-425
[2]   GAMMA-IRRADIATION OF PRETRANSPLANT BLOOD-TRANSFUSIONS FROM UNRELATED DONORS PREVENTS SENSITIZATION TO MINOR HISTOCOMPATIBILITY ANTIGENS ON DOG LEUKOCYTE ANTIGEN-IDENTICAL CANINE MARROW GRAFTS [J].
BEAN, MA ;
GRAHAM, T ;
APPELBAUM, FR ;
DEEG, HJ ;
SCHUENING, F ;
SALE, GE ;
STORB, R .
TRANSPLANTATION, 1994, 57 (03) :423-426
[3]  
Champlin RE, 2000, BLOOD, V95, P3702
[4]  
DENNIS D, 1990, ACCESS, V2, P1
[5]  
Gale RP, 1998, BLOOD, V91, P1810
[6]  
Gale RP, 1996, LEUKEMIA, V10, P13
[7]   CLINICAL MANIFESTATIONS OF GRAFT VERSUS HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL-A-MATCHED SIBLING DONORS [J].
GLUCKSBERG, H ;
STORB, R ;
FEFER, A ;
BUCKNER, CD ;
NEIMAN, PE ;
CLIFT, RA ;
LERNER, KG ;
THOMAS, ED .
TRANSPLANTATION, 1974, 18 (04) :295-304
[8]  
HO WG, 1984, BRIT J HAEMATOL, V57, P155, DOI 10.1111/j.1365-2141.1984.tb08509.x
[9]  
Horowitz MM, 1996, BONE MARROW TRANSPL, V17, pS5
[10]   Interferon alfa as primary treatment of chronic myeloid leukemia: long-term followup of 71 patients observed in a single center [J].
Kloke, O ;
Opalka, B ;
Niederle, N .
LEUKEMIA, 2000, 14 (03) :389-392